Key result
Uninterrupted DOAC is compared to temporary interruption for periprocedural bleeding and ischemic outcomes during coronary procedures.
Why the study?
Periprocedural management of direct oral anticoagulation in patients undergoing elective invasive coronary angiography or PCI remains debated.
Does uninterrupted DOAC therapy reduce in-hospital bleeding in patients using DOAC and scheduled for elective invasive coronary angiography or percutaneous coronary intervention compared to interrupted therapy?
Does uninterrupted DOAC therapy reduce in-hospital bleeding in patients using DOAC and scheduled for elective invasive coronary angiography or percutaneous coronary intervention compared to interrupted therapy?
Answers are grounded in this paper and cite their sources.
The SLIM-2 trial will provide critical evidence on the safety of uninterrupted versus interrupted DOAC therapy in patients undergoing elective ICA or PCI.
BACKGROUND: The periprocedural management of elective invasive coronary angiography (ICA) or percutaneous coronary intervention (PCI) of patients using direct oral anticoagulation (DOAC) remains debated. This trial aims to evaluate whether continuing DOAC therapy is as safe as temporary interruption, by comparing in-hospital and 30-day bleeding and ischemic outcomes. METHODS: The South Limburg Myocardial Infarction 2 (SLIM-2) trial (NCT04977076) is an investigator-initiated, multicenter, randomized controlled trial. A total of 1270 patients using DOAC and scheduled for elective ICA or PCI will be randomized in a 1:1 ratio to uninterrupted or interrupted therapy. The primary endpoint is in-hospital bleeding, classified as type 2, 3 or 5 according to the Bleeding Academic Research Consortium (BARC). Secondary endpoints are 30-day bleedings, major adverse cardiac and cerebrovascular events (MACCE), and net adverse clinical events (NACE, MACCE plus bleeding events). CONCLUSION: The SLIM-2 trial is the first large-scale randomized controlled trial to evaluate the safety of uninterrupted DOAC therapy in elective ICA and PCI. Its results will provide critical evidence to guide periprocedural anticoagulation management and may inform future clinical practice guidelines. TRIAL REGISTRATION: The trial is registered at ClinicalTrials.gov with number NCT04977076, https://clinicaltrials.gov/study/NCT04977076?term=NCT04977076&viewType=Card&rank=1.
No takes yet. Share an insight, caveat, or question.
Janssen et al. (2026) studied this question. Uninterrupted direct oral anticoagulation during elective coronary procedures is being compared to temporary interruption to evaluate periprocedural bleeding and ischemic outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: